Stocks of Abbvie Inc (NYSE:ABBV) traded higher last session on Wall Street, up 0.26% to $186.11.
ABBV stock price is now -1.27% away from the 50-day moving average and -1.61% away from the 200-day moving average. The market capitalization of the company currently stands at $328.75B.
With the price target maintained at $205, Citigroup recently Downgraded its rating from Buy to Neutral for Abbvie Inc (NYSE: ABBV). On April 22, 2025, Cantor Fitzgerald recently initiated its ‘Overweight’ rating on the stock quoting a target price of $210, while ‘BofA Securities’ rates the stock as ‘Neutral’
In other news, Stewart Jeffrey Ryan, EVP, CHIEF COMMERCIAL OFFICER sold 58,832 shares of the company’s stock on Mar 31 ’25. The stock was sold for $12,359,504 at an average price of $210.08. Upon completion of the transaction, the EVP, CHIEF COMMERCIAL OFFICER now directly owns 53,234 shares in the company, valued at $9.91 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 31 ’25, Officer Stewart Jeffrey Ryan bought 58,832 shares of the business’s stock. A total of $12,359,897 was incurred on buying the stock at an average price of $210.09. A total of 0.09% of the company’s stock is owned by insiders.
During the past 12 months, Abbvie Inc has had a low of $153.58 and a high of $218.66. As of last week, the company has a debt-to-equity ratio of 49.22, a current ratio of 0.76, and a quick ratio of 0.64.
The net profit margin was 7.24% and return on equity was 88.15% for ABBV. The company reported revenue of $13.34 billion for the quarter, compared to $12.31 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8.39 percent.
